INTRODUCTION
Growing evidence has implicated sleep as a key player in the regulation of appetite, metabolic and immune functions. 1 In recent studies, suboptimal sleep duration has been linked to serious health problems, including obesity, insulin resistance, type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, and cancer. Sleep disorders, described as difficulty initiating or maintaining sleep or non-restorative sleep, are highly prevalent and often under-diagnosed in the U.S. 42, 43 In particular, 10% to 15% of U.S. adults are affected by insomnia. 44 Also, 3% to 7% of men and 2% to 5% of women have diagnoses of obstructive sleep apnea (OSA), whereas 82% of men and 93% of women with moderate to severe OSA may be undiagnosed. 45 Identification of modifiable risk/protective factors for inadequate sleep is a prerequisite for the design, implementation, and evaluation of preventive strategies aimed at reducing its health impact. Whereas dietary habits 46, 47 and sedentary lifestyle [48] [49] [50] [51] [52] [53] [54] have recently been correlated with sleep, little research has been done on endocrine disruptors. Bisphenol-A (BPA) is a carbon-based synthetic compound used in the manufacturing of polycarbonate plastics, epoxy resins, and food and beverage containers. [55] [56] [57] [58] [59] It is a ubiquitous endocrine disruptor with estrogenic activity and is known to exert a wide variety of metabolic effects leading to reproductive and thyroid hormone dysregulation, weight gain, glucose intolerance, insulin resistance, type 2 diabetes, metabolic syndrome, cardiovascular disease, and fatty liver disease. [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] Recent literature reviews have pointed out the heterogeneity of epidemiologic evidence linking BPA exposure to various health outcomes, rendering the magnitude of the association difficult to estimate via metaanalyses. [70] [71] [72] BPA may impact suboptimal sleep and sleep disorders indirectly via its potential role in cardiometabolic risk factors and health problems. [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] A direct impact of BPA on the muscle function in the upper airway leading to OSA has also been suggested based on analogous findings from biomedical research. 73 Although the link between BPA and sleep appears to be biologically plausible, to date, only one study has correlated sleep issues with high levels of BPA. 73 The aim of this cross-sectional study is to evaluate level of BPA and its relationship to sleep adequacy (sleep duration, help-seeking behavior for sleep problems, and diagnosis with sleep disorders) in a nationally representative sample of U.S. adults, by performing secondary analyses using 2005-2010 National Health and Nutrition Examination Surveys (NHANES) data. We hypothesize that BPA level is inversely related to sleep duration and has a negative impact on sleep problems and disorders.
METHODS

National Health and Nutrition Examination Surveys 2005-2010
The NHANES is a program of studies conducted by the National Center for Health Statistics, a division of the Centers for Disease Control and Prevention (CDC), to assess the health and nutritional status of U.S. children and adults and to determine the prevalence of major diseases and their risk factors. 74, 75 The NHANES uses stratified multistage cluster sampling with oversampling of African Americans, Asians, Hispanics and adults 60 years and older. 74 Demographic, socioeconomic, and nutritional data were collected through in-person interviews, physical examinations and laboratory tests. 74, 75 Study Participants Since 1999, NHANES has become a continuous surveillance system. We selected 31,034 NHANES participants from three consecutive waves, namely, 2005-2006 (n = 10,348), 2007-2008 (n = 10,149), and 2009-2010 (n = 10,537).We excluded pregnant women (n = 507), individuals younger than 20 years (n = 13,902), and those with missing data on BPA (n = 23,133) and/or sleep-related questions (n = 11,467). The final sample consisted of adult non-pregnant 2005-2010 NHANES participants who were 20 years or older, and had no missing data on key variables of interest (n = 5,034).
Variable Definitions
Bisphenol-A Level
Spot urine samples were obtained from a one-third random subset of NHANES participants. Total urinary BPA, both conjugated and free, was analyzed by online solid-phase extraction coupled to high performance liquid chromatography (HPLC)-isotope dilution tandem mass spectrometry by the Division of Environmental Health Laboratory Sciences at the National Center for Environmental Health, CDC. 68 The details of quality assurance and quality control procedures, including coefficients of variation (CV of 8.1% to 18.6% for the low BPA quality control pools and 5.7% to 12.1% for the high BPA quality control pools) and lower limits of detection (LLOD/√2 or 0.28 ng/mL), were described elsewhere. 68 After careful examination of its distributional properties, we analyzed BPA level as a loge-transformed continuous variable and in quartiles (< 0.9 ng/mL; 0.9 to < 1.9 ng/mL; 1.9 to < 3.7 ng/mL; 3.7+ ng/mL). We used quartiles instead of tertiles or quintiles to maximize our ability to detect a relative risk of ~1.3, assuming that the proportion having the outcome is 0.1 with α = 0.05 and β = 0.2.
Sleep Adequacy
Three questions related to sleep adequacy were available in all 3 waves (2005-2006, 2007-2008, and 2009-2010) of NHANES data as follows: "How much sleep do you usually get at night on weekdays or workdays?" (Q1: Sleep duration), "Have you ever told a doctor or other health professionals that you have trouble sleeping?"(Q2: Help-seeking behavior for sleep problems) and "Have you ever been told by a doctor or other health professional that you have a sleep disorder?" (Q3: Diagnosis with sleep disorders). Responses to Q1 were measured on a continuous scale as number of hours, and responses to Q2 and Q3 were dichotomous "yes" or "no" 76 ; Q1 was also analyzed as a categorical variable using 3 distinct definitions based on recent studies of NHANES data, namely: definition 1 ("short sleep (yes): < 6 h," "short sleep (no): ≥ 6 h"); 43 definition 2 ("short sleep: < 7 h," "normal sleep: 7-8 h," "long sleep: > 8 h"); 76 definition 3 ("very short sleep: < 5 h," "short sleep: 5-6 h," "normal sleep: 7-8 h," "long sleep: ≥ 9 h"). (35 in) in women), self-rated health (excellent/very good/good, fair/poor), depressive symptoms based on the 9-item Patient Health Questionnaire (PHQ) total score (High: ≥ 10, Low: < 10), and adjusted creatinine level which was calculated based on equations described by Silver and coworkers. 68 Of note, the normal creatinine levels are estimated to be 0.6 to 1.2 mg/dL in adult males and 0.5 to 1.1 mg/dL in adult females.
Statistical Analysis
Statistical analyses were performed using STATA version 12 (STATA Corporation, College Station, TX). Whereas frequencies and percentages were computed for categorical variables, means and standard errors of the mean (SEM) were computed for continuous variables. Unadjusted (Model I), age-and sexadjusted (Model II) as well as fully adjusted (Model III) models were constructed for BPA as a predictor of sleep adequacy, using 'svy:reg' for continuous outcomes, 'svy:logit' for binary outcomes and 'svy:ologit' for ordinal outcomes. Measures of association were presented as beta coefficients with their 95% confidence intervals (CI) for linear regression models and odds ratios (OR) with their 95% CI for logistic regression models. Sampling weights were used to produce correct population estimates accounting for differential probabilities of selection and adjusting for non-coverage, non-response, and over-sampling of subpopulations. Two-sided statistical tests were performed at an α level of 0.05.
RESULTS
Between 2005 and 2010, 5,034 participants met inclusion criteria in this study; 2,564 were men and 2,470 were women. Table 1 details the demographic, socioeconomic, lifestyle, and health characteristics of the study participants by sex. Overall, the mean (± SEM) for age, BMI, waist circumference, depressive symptoms, and adjusted creatinine level were 47.0 ± 0.35 years, 28.7 ± 0.1 kg/m 2 , 97.9 ± 0.4 cm, 2.8 ± 0.08, and 909614.2 ± 13896.9 mg/dL, respectively. Furthermore, 24% were ≥ 60 years, 70% were non-Hispanic White, 57% had more than high school education, 58% were married, 63% had poverty income ratio > 2, 53% never smoked, and 76% drank alcohol in the past 12 months. Also, 35% had BMI ≥ 30 kg/m 2 , 52% had a high waist circumference, 84% had excellent, very good, or good self-rated health, and 6% had high Bisphenol-A and Sleep in the United States-Beydoun et al. depressive symptoms. All these characteristics differed significantly by sex, with the exception of race, education, and self-rated health. BPA levels and sleep adequacy of the study participants by sex are presented in Table 2 . Overall, the mean (± SEM) for BPA level and duration of sleep were 4.2 ± 0.4 ng/mL and 6.9 ± 0.03 h, respectively. Furthermore, 87% reported sleeping ≥ 6 h, 55% 7 to 8 h, and 7% ≥ 9 h. Moreover, 24% reported ever telling a doctor that they had trouble sleeping, and only 8% were ever diagnosed with a sleep disorder. All these characteristics were significantly different among men and women, with the exception of the binary definition (< 6 h vs. ≥ 6 h) of sleep duration. Table 3 The categorical definitions 1 (short sleep (yes): < 6 h, short sleep (no): ≥ 6 h) and 3 (very short sleep: < 5 h, short sleep: 5-6 h, normal sleep: 7-8 h, long sleep: ≥ 9 h) for sleep duration were inversely and significantly related to log e-transformed BPA level in unadjusted, sex-and age-adjusted and fully adjusted models. By contrast, the categorical definition 2 (short sleep: < 7 h, normal sleep: 7-8 h, long sleep: > 8 h) for sleep duration was inversely and significantly related to logetransformed BPA level only in the unadjusted and sex-and age-adjusted models. When defined as quartiles, BPA level was inversely and significantly related to categorical definition 1 of sleep duration in the unadjusted model as well as categorical definitions 2 and 3 of sleep duration in the unadjusted and sex-and age-adjusted models. Table 4 presents urinary BPA level as a predictor of selfreported sleep problems in unadjusted, sex-and age-adjusted and fully adjusted models. Clearly, only unadjusted models yielded significant and positive relationships between having told a doctor that he/she had trouble sleeping and urinary BPA level defined either as a continuous variable (OR = 1.08, 95% CI: 1.01, 1.16) or in quartiles (Q4 vs. Q1: OR = 1.24, 95% CI: 1.01, 1.52). By contrast, no significant relationship was observed between urinary BPA level and ever being told by a doctor that he/she had a sleeping disorder in the 3 models. 
Total (n = 5,034)
Males (n = 2,564) Females (n = 2,470) P value Bisphenol-A (ng/ml) n = 5,034 n = 2,564 n = 2,470 Mean ± SEM 4.2 ± 0.4 4.4 ± 0.5 4.0 ± 0. 
DISCUSSION
In this cross-sectional study, we investigated whether BPA was associated with sleep adequacy in a nationally representative sample of U.S. adults in whom self-reported sleep duration, help-seeking behavior for sleep problems, and diagnosis with sleep disorders were considered as the main outcomes of interest. Consistent with our hypotheses, the results indicated that loge-transformed BPA level was inversely related to sleep duration defined, in hours as a continuous variable, a dichotomous variable (≥ 6 vs. < 6) or an ordinal variable (≥ 9, 7-8, 5-6, < 5), after adjustment for confounders. By contrast, helpseeking behavior for sleep problems and diagnosis with sleep disorders were not significantly associated with loge-transformed BPA level in the fully adjusted models. Also, when BPA level was defined in quartiles, its relationship with sleep adequacy did not reach statistical significance after controlling for demographic, lifestyle, and health characteristics of the study sample. The latter finding suggests a complex nonlinear relationship between BPA and indicators of sleep adequacy. Emerging evidence suggests that BPA, atrazine, dichlorodiphenyltrichloroethane, diethylstilbestrol, dioxin, phthalates, polychlorinated biphenyls, organotins, and other endocrine disruptors may have negative health effects. [84] [85] [86] [87] [88] [89] [90] [91] Endocrine disruptors are lipophilic substances that usually act as transcription factors for nuclear hormone receptor superfamily and can either mimic or block the action of endogenous sex hormones, resulting in irreversible alterations or reversible alterations in patterns of gene expression. 84, [86] [87] [88] [89] [90] [91] Sex steroids (androgens and estrogens) play an important role in establishing and maintaining adipose tissue 84, 85 and in conjunction with growth hormones can mobilize lipids and have anti-adipogenic effects; their effects are counteracted by insulin and cortisol that have adipogenic effects. 84 Exposure to endocrine disruptors such as BPA is thought to promote adiposity typical of Cushing syndrome, polycystic ovary syndrome, growth hormone deficiency, menopause, aging, alcoholism, and depression. 84, 88 Since the 1960s, BPA has been produced in large quantities for the manufacturing of flame retardants, dental sealants and fillings, adhesives, protective coatings, infant feeding bottles, food and mineral water storage containers, and food and beverage can linings. 84, [92] [93] [94] [95] [96] [97] [98] Although studies have suggested that low-dose BPA exposure may be associated with increased reproductive and cancer risks, [99] [100] [101] [102] [103] [104] [105] regulatory bodies in the U.S., Canada, and Europe have distinct views on whether BPA should be considered a hazardous substance. 106 So far, a limited number of studies have used a nationally representative sample to investigate health effects of BPA, and several of these studies, most of which used NHANES data, have linked high BPA to obesity-related cardiometabolic risk factors and conditions. 69, 92, 93, [107] [108] [109] The finding of an inverse relationship between sleep duration and BPA level is consistent with the current evidence that BPA is a chemical substance that has the capacity to bind nuclear and membrane surface estrogen receptors, resulting in obesity-related disturbances which can potentially mediate suboptimal sleep. 58, 59, 64, 66, 69 However, our results also suggest that BPA level may be negatively associated with sleep duration, independently of BMI or waist circumference, both of which are indices of obesityrelated disturbances. Therefore, it is also plausible that BPA may have an adverse impact on muscular function in the upper airway, causing sleep disorders such as OSA, as suggested by biomedical researchers. 41 In-depth analyses are needed to evaluate the mediating role of obesity-related cardiometabolic risk factors and conditions, including components of the metabolic syndrome, in the observed relationship between BPA and sleep duration. While the proposed biological mechanisms are plausible, reverse causality cannot be ruled out as a potential explanation for the observed associations. In fact, it is also plausible that individuals who experience shorter sleep are more likely to experience environmental BPA exposure which, in turn, assumes a state of wakefulness.
To our knowledge, this is the first study examining whether BPA may be causally or non-causally linked to adequacy of sleep in a nationally representative sample of U.S. adults. Previous studies have used NHANES data to examine correlates of sleep, including race/ethnicity, 43, 83 anxiety, 75 and functional health. 43 In a recent study, Erden and colleagues 41 evaluated the associations among OSA, BPA, vitamin D, and parathyroid hormone levels using a sample of 128 subjects who had undergone polysomnography and were classified as control (n = 43), moderate OSA (n = 23), or severe OSA (n = 62). 41 Consistent with our findings, their results indicated that while vitamin D level was lower in both OSA groups and PTH was higher in OSA groups than in the control subjects, and BPA levels were higher in severe OSA than moderate OSA and controls. 41 Nevertheless, our findings should be interpreted with caution and in light of several limitations. First, the study design is cross-sectional, which precludes establishing cause-and-effect relationships among variables under study. Second, analyses were based on previously collected data reducing flexibility in the definition of outcome, exposure, and covariate variables. Third, BPA metabolites were assessed by a single assay in NHANES, which may not represent diurnal changes in BPA levels. Fourth, the study sample was selected on the basis of availability of exposure and outcome data, which may have resulted in selection bias. In particular, the inclusion and exclusion criteria that define the selected subset of NHANES 2005-2010 subjects may have influenced the effectiveness of weighting variables. Further analyses suggested that the selected and non-selected adult subjects differed significantly on sex, age, race/ethnicity, and education. Fifth, NHANES assessed adequacy of sleep using self-report rather than polysomnography or medical records data, which may have led to non-differential misclassification of the outcome variables of interest, potentially biasing measures of association towards the null value. Moreover, the question pertaining to sleep duration was limited in scope as it only considered week or workdays. Considering the existence of sleep compensation (short sleep during week or workdays and longer sleep on weekends or free days), the general sleep time is underestimated. Also, at least one of the sleep-related outcomes is a rare event with a prevalence of less than 10%, reducing our ability to detect an association with BPA exposure.
Sixth, although numerous covariates were included in the multivariable models, we cannot rule out residual confounding as an explanation for the observed associations due to uncontrolled factors such as area of residence and diet quality. Seventh, although sex differences were observed, we could not conduct stratified analyses according to sex as a result of sample size limitations. Finally, our findings can only be generalized to adult men and women, and further research is needed to evaluate these relationships in adolescents and children.
In conclusion, secondary analyses of 2005-2010 NHANES data involving U.S. adults suggests that sleep duration, but not help-seeking behaviors related to poor sleep, may be inversely related to BPA level, with implications for primary and secondary prevention. Regulation of environmental BPA level could potentially reduce the risk of adverse health outcomes, including poor sleep. Also, monitoring of BPA level by healthcare professionals could help identify patients at high risk for poor sleep and aid in the management of patients experiencing poor sleep. Our results support the idea that excessively high levels of BPA may, directly or indirectly, be linked to poor sleep. Further research is needed to better understand what specific environmental exposures may have led to excessive levels of BPA and consequently adverse outcomes such as inadequate sleep. ABBREVIATIONS BMI, body mass index BPA, Bisphenol-A CDC, Centers for Disease Control and Prevention CI, confidence interval CV, coefficient of variation HPLC, high performance liquid chromatography LLOD, lower limit of detection NHANES, National Health and Nutrition Examination Surveys OR, odds ratio OSA, obstructive sleep apnea
